

CURRICULUM VITAE

A. Personal Information:

Name in Full: Maurizio Bonacini, M.D., A.G.A.F.
Business Address: C.E.O.
Mission Gastroenterology and Hepatology Inc.
2300 Sutter Street, suite 202
San Francisco, CA 94115

Research Office:
Quest Clinical Research
2300 Sutter Street, suite 202. San Francisco CA 94115.

Email: bonacim08@ gmail.com
Business Phone: (415) 353-0800
Place of Birth: Lecce, Italy
Citizenship: U.S.A.

B. Education:

Undergraduate: Scuola Saffi, Rome, Italy
1967 to 1970
Lycee Jean XXIII, Kolwezi, Zaire
1970 to 1972
Seminaire de Bastogne, Bastogne, Belgium
1972 to 1975

Graduate: Universite Catholique de Louvain
School of Medicine, Brussels, Belgium
M.D. degree awarded on July 10, 1982
"Magna cum Laude".

Post-Graduate: First-year Resident in Internal Medicine
Universite Catholique de Louvain Residency Program
1982 to 1983

Internship: Internal Medicine, Booth Memorial Medical Center
Flushing, New York 11355
Affiliated with the New York University
Medical Center, New York, New York
1983 to 1984

Residency: Internal Medicine, Booth Memorial Medical Center
Affiliated with the New York University
Medical Center, New York, New York
1984 to 1986

Fellowships: 1. Gastroenterology
Los Angeles County-University of
Southern California Medical Center

Gastroenterology Section

Los Angeles, California
July 1986 to June 1988

2. Hepatology
University of Southern California
Liver Unit, Downey, California
July 1988 to July 1989

Licensure: California, (1996) (Certificate A 043170)
DEA (BB792184)
Supervisor of Physician Assistants (SA 20627)

B. Areas of interest

1. Hepatitis C
2. Liver fibrosis
3. Non alcoholic fatty liver disease
4. Adherence to medications

C. Professional Activities:

- Past Appointments:
1. Assistant Professor of Medicine
Section of Gastroenterology
University of Missouri-Kansas City
School of Medicine
September 1989 to April 1992
 2. Assistant Professor of Clinical Medicine
University of California, Irvine
August 1992 to July 1993
 3. Visiting Assistant Professor of Clinical Medicine
University of Southern California,
Los Angeles, California
August 1993 to 1998
 4. Associate Professor of Clinical Medicine
University of Southern California,
Los Angeles, California
December 1998 to December 2001.
 5. Physician to Italian Consulate San Francisco May 8, 2008 to Dec 1, 2021

- Current Appointments:
1. Associate Clinical Professor of Medicine
University of California San Francisco
San Francisco, California
July 8, 2002 to date
 2. Chief Executive Officer: Mission Gastroenterology and Hepatology.
January 8, 2012 to date.
 3. Contractor: Quest Clinical Research, San Francisco. August 1, 2014
to date
 4. Physician for SFO airport for ITA airways

D. Professional organizations:

Board Certified: Diplomate of the American Board
 Internal Medicine, September 1986
 Number 107325
 Diplomate of the American Board of
 Gastroenterology, November 1989
 Number 107325
 Diplomate Transplant Hepatology 2006

Languages: English
 Italian
 Spanish
 French

1. Member of the American College of Physicians, July 1, 1986: #010086
2. Member of the American Gastroenterological Association, May 1990.
3. Member of the Italian-American Medical Association, June 1987-December 1995.
Secretary, Italian-American Medical Association, January 1993-December 1995.
4. Member and Vice-President, Liver Research and Education Foundation, Los Angeles, CA,
December 1993.
5. Member, Southern California Society of Gastroenterology, February 1994 December 2001.
6. Member, American Association for the Study of Liver Diseases, November 1995.
7. Councilor for Hepatology, Southern California Society of Gastroenterology, February 1998-Jan
2001.
8. Member, American Liver Foundation Medical Advisory Committee, Los Angeles Chapter,
March 1, 1999-2002.
9. Education Committee, Southern California Society of Gastroenterology, January 2001-2002.
10. National Italian American Foundation (NIAF); Silver Council member, January 2005.
11. Official Physician of the Italian Consulate of San Francisco, appointed on May 8, 2008 to
December 2021.
12. Member, American Liver Foundation Medical Advisory Committee, Northern California
Chapter, March 1 2006-present.
13. Fellow, American Gastroenterological Association: 2012-present

E. Service to Professional Publications:

1. Digestive Diseases and Sciences 1989, 1993, 2002, 2010.
2. American Journal of Gastroenterology 1992-2006.
3. American Board of Internal Medicine: Contributor to the Gastroenterology recertification
process, 1992.
4. Gastrointestinal Endoscopy 1993, 1994, 1999.
5. Gastroenterology 1997, 2001, 2002, 2006-2010.
6. Clinical Infectious Diseases 1997, 2000, 2001, 2006, 2007.
7. Italian Journal of Gastroenterology and Hepatology 1998, 1999.
8. Hepatology 1998, 1999, 2000, 2004-2007
9. Journal of Infectious Diseases, 1999, 2002, 2003, 2005, 2007, 2009.
10. AIDS, 2000, 2006-2010.
11. Journal of AIDS, 2000-2003-2007, 2009.
12. Digestive and Liver Disease, 2000.
13. Expert Review of Molecular Diagnostics, 2001.

14. HIV Clinical trials, 2001, 2002.
15. Journal of Hepatology, 2002, 2004, 2007.
16. American Journal of Clinical Dermatology, 2002.
17. Journal of Medical Virology 2002
18. Drug safety, 2002
19. Clinical Gastroenterology and Hepatology, 2003-2004, 2008, 2018
20. American Journal of Medicine 2004
21. Alimentary Pharmacology and Therapeutics, 2004-2006
22. Journal of Viral Hepatitis 2004, 2006
23. Liver International 2004
24. Nature: Clinical Practice Gastroenterology & Hepatology 2005
25. Antiviral therapy 2005, 2006
26. Epidemiology and Infection 2006
27. Nature Clinical Practice Endocrinology & Metabolism, 2008
28. International Editor, Nigerian Journal of Gastroenterology and Hepatology, 2009 to date

F. Invited Presentations: [1-32 upon request]

33. Pharmacy Council on Hepatitis and Liver Disease. Chair: Dr. Joseph Bick. New developments in Hepatitis B/C and HIV coinfection. California Medical Facility, Vacaville, CA. September 26, 2008.
34. American Liver Foundation Wellness lecture Series. New medications for hepatitis C. Walnut Creek, CA. October 9, 2007.
35. Course Director, Fifth Annual San Luis Obispo GI/Liver Update. San Luis Obispo, January 26, 2008.
36. Fifth Annual San Luis Obispo GI/Liver Update. Liver tests: the old and the new. San Luis Obispo, January 26, 2008.
37. ALF Northern California Chapter Symposium. Hepatitis B.HBV/Co-Infection. (HIV, HCV, and HDV – management & treatment). Cathedral Hill Hotel, San Francisco, CA 3/15/2008.
38. San Luis Obispo Hepatitis C Symposium. Dairy Creek Golf Club, San Luis Obispo, CA. Hepatitis C Treatment plan. October 25, 2008.
39. AASLD 2008: San Francisco, CA. Co-chair: Meet the Professor Luncheon: HIV and hepatitis coinfection. Nov 1, 2008.
40. Chair: The 6th Gi/Liver Symposium. San Luis Obispo, CA. AASLD 2008 Review: January 31, 2009.
41. 6th Gi/Liver Symposium. San Luis Obispo, CA. Management of cirrhosis in primary care. January 31, 2009.
42. Chair. HBV Treatment Controversies 2009: A debate. Sponsored by The Johns Hopkins University School of Medicine; produced in collaboration with ViralEd LLC. San Jose, CA June 16, 2009.
43. Chair. HBV Treatment Controversies 2009: A debate. Sponsored by The Johns Hopkins University School of Medicine; produced in collaboration with ViralEd LLC. San Francisco, CA June 17, 2009.
44. Chair. The 7th Yearly GI/Liver Symposium. San Luis Obispo, CA. Post AASLD 2009 Review. San Luis Obispo, CA. January 30, 2010.
45. Hepatitis C in end stage Renal Disease. San Jose, April 20, 2010. Maximizing Opportunities for Kidney Transplant Santa Clara Kidney Symposium. Santa Clara, CA.
46. Transplantation Grand Rounds. HCV advances in 2011. CPMC November 11, 2010.
47. Hepatitis C update, emphasis on HIV. HIV Grand rounds, CPMC Davies campus, San Francisco. June 2011.
48. The San Francisco Center For Liver Disease: HCV Update from AASLD 2011. Kabuki Hotel, San Francisco, December 3, 2011.
49. Update on HCV infection. Gastroenterology Grand Rounds, CPMC Pacific Campus. December

- 15, 2011.
50. St. Luke's Hospital Medicine Grand Rounds: Update on therapy for chronic hepatitis C. San Francisco, September 13, 2012.
 51. CPMC Gastroenterology Grand Rounds: Update on antiviral therapy for chronic hepatitis C. San Francisco, February 14, 2013.
 52. CPMC Gastroenterology Grand Rounds: Liver biopsy vs. non invasive fibrosis tests. San Francisco, February 14, 2013.
 53. CPMC Davies HIV Grand Rounds: Non invasive tests to measure liver fibrosis: Is liver biopsy being supplanted? Davies Campus, San Francisco, CA August 20, 2014
 54. Landis, Charles¹; Kim, Yoona²; Pitney, Caroline¹; McKoin, Lee¹; Bonacini, Maurizio³. Wirelessly observed therapy for oral HCV treatment. Presented at DDW 2017; Chicago, IL May 9 2017
 55. 5th NASH Symposium, Presenter: Metabolic syndrome, Race and NAFLD. November 28, 2021

G. CME courses attended:

AASLD, the Liver meeting: yearly since 1994
 EASL Meeting: yearly since 2006 (except 2014)
 DDW 2017

K. Teaching mentoring:

Assistant professor of medicine and Docent UMKC 1989-1991
Assistant and Associate professor USC 1992-2002
Program Director CPMC Transplant Hepatology fellowship 2009-2011

L> Teaching Aids:

1. University of Southern California, Ward 5P21, HIV Treatment Guidelines: Abdominal Pain and Hepatobiliary Problems.
2. Los Angeles County Department of Health Services: Guidelines on the use of the combination Interferon-ribavirin at the LAC-USC Medical Center. Submitted 6/99.
3. CME Monograph. Managing complexities in the treatment of HIV/HCV coinfecting patients. Sponsored by Rush University Medical Center. February 2004.

M. Mentoring Hours**N. Research Grants:****Principal Investigator:**

1. Sarah Morrison bequest grant. Prospective evaluation of chronic diarrhea in patients with human immunodeficiency virus (HIV) infection. \$30,000 over two years. Awarded July 1, 1990.
2. Liver Research Education Foundation, Los Angeles, CA. Influence of HIV infection on chronic hepatitis B infection. \$4,300 awarded December 15, 1993.
3. Chapman Research Fund, Palo Alto, CA. The influence of human immunodeficiency virus on parameters of hepatitis C virus replication, liver damage and carcinogenesis in dually infected patients. \$16,264 over two years, awarded July 1, 1994.
5. Schering-Plough, Kenilworth, NJ. Levels of circulating cytokines in patients with chronic hepatitis C, before and after Intron A therapy. \$13,000 awarded 2/1/95.
6. American College of Gastroenterology. The expression of Fas antigen in liver tissue of patients with HIV+HCV coinfection. \$6,000 awarded 4/1/95.
7. Schering-Plough, Kenilworth, NJ. Effect of Ribavirin-Intron A as treatment for Hepatitis C in nonresponders to Intron A alone. \$30,000 awarded 3/1/97.

8. P.I.: AmFar, NY, NY. Effect of a Ribavirin-Intron A combination on Hepatitis C in Patients With HIV Infection. \$9,000.
9. P.I.: Roferon treatment of hepatitis C patients co-infected with HIV: a comparison of different induction and maintenance schedules. \$25,000.
10. P.I. Boehringer Ingelheim. Nevirapine pharmacokinetics in patients with HIV/HCV coinfection. January 2004.
11. P.I.: Prospective evaluation of anemia after liver transplantation. Therapy with Erythropoietin. Ortho-Biotech, May 2003: \$52,000.
12. P.I.: Bristol-Myers-Squibb Protocol AI463038: A Phase II Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Who Have Hepatitis B Viremia while on Lamivudine Treatment, May 2003:\$ 40,000.
13. P.I.: Roche Pharmaceuticals. A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys□ 180 µg plus Copegus□ 1000 or 1200 mg to the Currently Approved Combination of Pegasys□ 180 µg plus Copegus□ 800 mg in Interferon-naïve Patients with Chronic Hepatitis C Genotype 1 virus infection coinfecting with human immunodeficiency virus. April 2006 ; \$185,000.
14. P.I.: Boehringer Ingelheim Pharmaceuticals, Inc., Doc. No. U07-3155, BI Trial No.: 1220.2.. Safety, Antiviral Activity, and Pharmacokinetics of Multiple Rising Oral Doses of BI 201335 NA as Oral Solution in Treatment-Naïve Patients with Chronic Hepatitis C Infection for 14 Days Monotherapy Followed By Combination with Pegylated Interferon and Ribavirin for an Additional 14 Days (Double-Blind, Placebo-Controlled); and in Treatment –Experienced Patients with Chronic Hepatitis C Infection For 28 Days as Combination Therapy with Pegylated Interferon and Ribavirin (Open-Label). November 2007: \$ 100,000.
15. P.I.: Boehringer Ingelheim Pharmaceuticals, Inc., Trial No.: 1220.5 Safety, Antiviral Activity, and Pharmacokinetics of Multiple Rising Oral Doses of BI 201335 NA in Treatment-Naïve Patients with Chronic Hepatitis C Infection. March 2009: \$ 30,000.

O. Peer Review publications [1-32 upon request]

33. Alexandra Gibas⁵, Scott J Cotler⁶, Marc Deschenes⁷, Kelly Kaita⁸, Gian S Jhangri. A Multicenter Study Of The Usefulness Of Liver Biopsy In Hepatitis C. *J Viral Hep* 2004;11(4):795-782.
34. Celona A, Prakash M, Kuo T, Bonacini M. Hepatitis C in a Los Angeles Public Hepatitis Clinic: Demographic and biochemical differences associated with race-ethnicity". *Clinical Gastroenterology and Hepatology* 2004;2:459-462.
35. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis coinfection. *Clin Infect Dis*. 2004 Mar 1;38 Suppl 2:S104-8.

36. Brau N, Kostman J, **Rodriguez Torres M, Procupek D, Bonacini M, Giffen C, Smith J, Frost K. Treatment of chronic hepatitis C in HIV/HCV-coinfecting patients with interferon alfa-2b plus full-course versus 16-week delayed ribavirin. *Hepatology* 2004;39:989-98.**
37. Bonacini M, Louie S, Bzowej N, Wohl AR Survival in patients with HIV infection and viral hepatitis B or C. A cohort study. *AIDS* 2004;18:2039-2045.
38. Vincent Soriano, Massimo Puoti, Maurizio Bonacini, Gary Brook, Antonietta Cargnel, Juergen Rockstroh, Chloe Thio, Yves Benhamou. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. *AIDS* 2005;19:221-240.
39. Daugherty T, Bonacini M. Management of hepatitis C in patients with HIV infection. *Expert Rev Anti Infect Ther* 2005 3(3):375-384.

40. Romagnuolo J, Andrews CN, Bain V, Bonacini M, Cotler S, Ma M, Sherman M. Simple clinical variables predict liver histology in hepatitis c: prospective validation of a clinical prediction model. *Scandinavian Journal of Gastroenterology* 2005 Nov;40(11):1365-71.
41. B Combes, SS Emerson, NL Flye, SJ Munoz, VA Luketic et al, Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (PBC). *Hepatology* 2005;42:1184-93.
42. Verma S, Wang H, Govindarajan S, Kanel G, Squires K, Bonacini M. Does Type and Duration of HIV Therapy Prior to a Liver Biopsy, Impact Histological Severity of Hepatitis C Related Liver Disease in HIV/HCV Coinfected Patients? *Clin Infect Dis* 2006; 42:262-70.
43. Assi M, McKinsey DS, Driks MR, O'Connor MC, Bonacini M, Graham B, Manian F. Gastrointestinal histoplasmosis in AIDS: report of 18 cases and literature review. *Diagnost Microbiol Infect Dis* 2006 55(3):195-201
44. Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A. More Advanced Hepatic Fibrosis in Hispanics with chronic Hepatitis C Infection: Role of Patient Demographics, Hepatic Necroinflammation and Steatosis. *Am J Gastroenterol* 2006; 101(8):1817-23.
45. Kohla M, Bonacini M. Pathogenesis of hepatitis C virus infection. *Min Gastroenterol Dietol* 2006;52:107-123.
46. Gabriel Chamie¹, Maurizio Bonacini², David Bangsberg^{1,3}, Christopher Hall⁴, Jack Stapleton⁵, E. Turner Overton⁶, Rebecca Scherzer⁷, Phyllis C. Tien. Factors associated with seronegative chronic hepatitis C virus infection in HIV-infection. *Clin Infect Dis* 2007 44(4):577-83.
47. Ira Inductivo-Yu, Atoya Adams, Robert G Gish, Adil Wakil, Natalie H Bzowej, R. Todd Frederick, Maurizio Bonacini. Mycophenolate Mofetil in Autoimmune Hepatitis Patients Not Responsive or Intolerant to Standard Immunosuppressive Therapy. *Clin Gastroenterol Hepatol* 2007;5:799-802.
48. Bonacini M, Govindarajan S, Kohla M, Lai MMC, Lindsay KL. Intrahepatic lymphocyte phenotypes in HCV infection; a comparison between cirrhotic and non-cirrhotic livers. *Minerva Gastroenterol Dietol* 2007;53:1-7.
49. Marion G. Peters, Adrian M. Di Bisceglie, Kris V. Kowdley, Nancy L. Flye, Velimir A Luketic, Santiago J. Munoz, Guadalupe Garcia-Tsao, Thomas D. Boyer, John R. Lake, Maurizio Bonacini and Burton Combes for the PUMPS Study Group. Differences between caucasian, african-american and hispanic patients with primary biliary cirrhosis in the USA. *Hepatology* 2007;46(3):769-75.
50. Bonacini M. Diagnosis and Management of Cirrhosis in Coinfected Patients. *JAIDS* 2007;45 (Suppl. 2):S38-S46.
51. Inductivo-Yu I, Bonacini M. Highly Active Antiretroviral Therapy-induced Liver Injury. *Current Drug safety* 2008 Jan;3(1):4-13
52. N Brau and The North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study. *J Hepatol* 2007;47:527-37.
53. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. *Gastroenterology*. 2008 Dec;135(6):1924-34,
54. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Rationale, design and conduct of the Drug-Induced Liver Injury Network (DILIN) Prospective Study. *Drug Safety* 2009;32:55-68.
55. Causality Assessment in Drug Induced Liver Injury Using a Structured Expert Opinion Process: Comparison to RUCAM. Don C. Rockey, Leonard B. Seeff, James Rochon, James Freston, Naga Chalasani, Maurizio Bonacini, Robert J. Fontana, and Paul H. Hayashi for the U.S. Drug-Induced Liver Injury. *Hepatology* 2010;6:2117-2126.
56. Martinez AF, Bonacini M, Roberts JP Image of the month: Portal Hypertensive Biliopathy *Arch Surg*. 2011 May;146(5):625-6.
57. Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, et al. Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. *J Hepatol*. 2011;(54)6:1114-1122

58. Bonacini M. Virologic and Clinical Outcomes in HIV/HBV Coinfected Patients on Tenofovir-Containing HAART. *Gastroenterology* 2010 Dec;139(6):1827-9.
59. Bonacini M. Alcohol Use Among Patients With HIV Infection. *Ann Hepatol.* 2011 Oct-Dec;10(4):502-7.
60. Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu MC, Groshen S, Bonacini M. Histological Versus Clinical Cirrhosis in Chronic Hepatitis C: Does Race/Ethnicity Really Matter? *Dig Dis Sci.* 2012 Mar;57(3):771-6.
61. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor- α antagonists: analysis of 34 cases. *Clin Gastroenterol Hepatol* 2013 May;11(5):558-564
62. Kohla M, Shaw R, Hisatake G, Osorio R, Maurizio Bonacini. Do Tumor Characteristics and Pre-Transplant Locoregional Therapy Predict Survival after OLT in Patients with Hepatocellular Carcinoma? *International Journal of Clinical Medicine* Vol.4 No.12A:25-31
63. French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky H. Hepatotoxicity Associated with the Use of Anti-TNF- α Agents. *Drug Saf.* 2016 Mar; 39(3): 199–208.
64. Bonacini M, Shetler K, Yu I, Osorio RW, Osorio R. Prognostic factors in 27 cases of Severe Hepatitis Due To Mushroom Poisoning. *Clin Gastroenterol Hepatol* 2017;15:776-9.
65. Younossi ZM, Ratziu V, Loomba R and the REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet.* 2019 Dec 14;394(10215):2184-2196
66. Bonacini M, Kim Y, Pitney C, McKoin L, Tran M, Landis C. Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. *JMIR* 2020;22(2):e15532
67. Bonacini M, Farah Kassamali, Swathi Kari, Nieves Lopez Barrera, Mohamed Kohla Racial differences in prevalence and severity of non-alcoholic fatty liver disease. *World J Hepatol* 2021;13(7):763-773
68. Ahmad J, Kleiner D, Bonacini M et al. Value of **liver biopsy** in the diagnosis of drug-induced **liver** injury. *J Hepatol* 2022;76:1070-1078.
69. Sulkowski et al. paper "Efficacy and safety of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection". *J Hepatol* 2022 (in press)
70. Yuen MF, Agarwal K, Ma X, i et al. "Efficacy and safety of vebicorvir in virally suppressed patients with chronic hepatitis B virus infection". *J Hepatol* 2022;77:642-652.

Book Chapters:

1. Bonacini, M. The spectrum of pancreatic disease in patients with human immunodeficiency virus infection. In: Prof G. Bianchi-Porro, Ed. *Le manifestazioni gastroenterologiche in corso di AIDS.* Verona: Edizioni Libreria Cortina;1992:103-113.
2. Bonacini M, Laine L. Esophageal disease in AIDS. In: G Friedman, ED Jacobson, RW McCallum, Editors. *Gastrointestinal Pharmacology and Therapeutics.* Lippincott-Raven, 1997.
3. Bonacini M. The liver in systemic diseases. In: N. Kaplowitz, editor. *Liver and biliary diseases,* 2nd edition. Williams and Wilkins, 1996.
4. Bonacini M, Laine L. Esophageal disorders in AIDS: Diagnosis and treatment. *Gastrointestinal Endoscopy Clinics of North America* 1998;8(4):811-824.
5. Bonacini M, Louie S, Weisman K. Hepatotoxicity of antiviral medications. In: Kaplowitz and DeLeve, Editors: *Drug-induced liver disease.* Marcel Dekker. New York 2002, pp. 519-548.
6. Govindarajan S, Bonacini M. Liver biopsy and histopathological diagnosis, 4th ed.. In: Yamada T, Editor. *Textbook of Gastroenterology.* Lippincott, Williams and Wilkins. Philadelphia 2008, pp. 2947-2975.
7. Govindarajan S, Bonacini M. Liver biopsy and histopathological diagnosis, 5th ed.. In: Podolsky DT, Editor. *Yamada's Textbook of Gastroenterology.* Lippincott, Williams and Wilkins. Philadelphia 2015.
8. Govindarajan S, Gong, Y, Bonacini M. Liver biopsy and histopathological diagnosis, 6th ed.. In:

Podolsky DT, Editor. Yamada's Textbook of Gastroenterology. Lippincott, Williams and Wilkins. Philadelphia 2022. 2814-2845.

Additional

- Best Doctors in America 2007-16.
- Clinical Infectious Diseases* Award for outstanding review 2008
- Fellow of the American Gastroenterological Association, January 2009
- Faculty; Gastroenterology and Hepatology Section: Faculty of 1000. August 8, 2011.
- America's best physicians 2023

1. Boehringer-Ingelheim: Nevirapine hepatic safety Advisory Board, 2002-4
2. Boehringer-Ingelheim: Tipranavir hepatic safety Advisory Board, 2005
3. Pfizer: Filibuvir Data safety monitoring Board. January 2010 to date.
4. Dynavax: Hepatitis B vaccine Advisory Board, September 2012.